| Latest Forum Topics / Biosensors |
 Post Reply
|
|
Is Biosensors a good buy?
|
||||||
|
A02041315
Senior |
22-Oct-2008 11:07
|
|||||
|
x 0
x 0 Alert Admin |
I GUESS SO
|
|||||
| Useful To Me Not Useful To Me | ||||||
|
XiaoMaGe888
Senior |
22-Oct-2008 10:50
|
|||||
|
x 0
x 2 Alert Admin |
May be slowly lai liao (personal view)) 
|
|||||
| Useful To Me Not Useful To Me | ||||||
|
|
||||||
|
AK_Francis
Supreme |
20-Oct-2008 18:19
Yells: "Happy go lucky, cheers." |
|||||
|
x 0
x 0 Alert Admin |
yoh, not sure whether biomatrix? but the techno to relief her about the same illustrated in paper. she needs to come back weeks later for 2nd artery opt. as doc there claimed she is old can't do twice at one go. she told us that one patient 3 arteries got stuck but before going for opt, he passed away liao. pse note that in the cardiology dept, all doc are chinese, including the head. didn't ask the nurses there as all of them also non chinese. I think it could be pay issue loh.
|
|||||
| Useful To Me Not Useful To Me | ||||||
|
PensionAlterEgo
Member |
20-Oct-2008 17:27
|
|||||
|
x 0
x 0 Alert Admin |
So this means BioMatrix is sold in Malaysia as well..
cool!
|
|||||
| Useful To Me Not Useful To Me | ||||||
|
AK_Francis
Supreme |
20-Oct-2008 16:47
Yells: "Happy go lucky, cheers." |
|||||
|
x 0
x 0 Alert Admin |
ha ha, just back fr JB, mother - in - law hosp owing to heart artery blockage. tks BIG which saved her life. |
|||||
| Useful To Me Not Useful To Me | ||||||
|
|
||||||
|
XiaoMaGe888
Senior |
20-Oct-2008 16:41
|
|||||
|
x 0
x 0 Alert Admin |
I also believe .So TCC CAFEnot far liao.
|
|||||
| Useful To Me Not Useful To Me | ||||||
|
ekekeg
Veteran |
20-Oct-2008 13:24
|
|||||
|
x 0
x 0 Alert Admin |
|
|||||
| Useful To Me Not Useful To Me | ||||||
|
dontalkrubbish
Member |
20-Oct-2008 11:33
|
|||||
|
x 0
x 0 Alert Admin |
As usual, after good news, BIG kanna sell down. What sort of lousy counter is this. Or should I say "cornered". Today quite a few counters either +ve or stay put.. cry till no tears left. |
|||||
| Useful To Me Not Useful To Me | ||||||
|
|
||||||
|
ekekeg
Veteran |
17-Oct-2008 13:39
|
|||||
|
x 0
x 0 Alert Admin |
Have not seen Bengster's posting for 1 week already. So far no news from him. Probably he is on holiday. No news is good news? 
|
|||||
| Useful To Me Not Useful To Me | ||||||
|
PensionAlterEgo
Member |
17-Oct-2008 09:04
|
|||||
|
x 0
x 0 Alert Admin |
Medtronic Endeavor Heart Stent Tied to Complications (Update3) By Michelle Fay Cortez and Alex Nussbaum Oct. 16 (Bloomberg) -- Medtronic Inc.'s drug-coated heart stent Endeavor had more complications than Johnson & Johnson's rival device to prop open arteries and didn't reduce the need for future treatment. The research presented at the Transcatheter Cardiovascular Therapeutics conference in Washington, D.C., raises questions about Endeavor's safety, which had been considered the device's edge in the intense battle for the $4 billion worldwide market for drug-coated stents. Medtronic is trying to revive Endeavor's sales, which slumped after Abbott Laboratories' Xience won U.S. approval in July and captured half the American market. ``Medtronic has done a good job promoting its safety, and this certainly calls that into question,'' said Alexandra J. Lansky, director of the Women's Health Initiative at the Cardiovascular Research Foundation, in an interview after she moderated a press conference about the findings today. Lansky, a cardiologist at New York-Presbyterian Hospital- Columbia University Medical Center, said she would no longer choose Endeavor as a first option for her patients based on what she called the ``sobering results.'' Medtronic's shares fell 83 cents, or 2 percent, to $40.01 at 4 p.m. in New York Stock Exchange composite trading. The company sank 15 percent after the study was presented, then rose with the overall market. Possible Explanations The study, with two others presented today at the medical conference, is ongoing and may have been skewed by blood-thinning drugs or by sicker patients receiving Medtronic's version of the mesh sleeves aimed at keeping arteries open, said Jens Flensted Lassen, lead investigator in the trial named Sort-Out III. The study results aren't likely ``a major game-changer'' because of the caveats, said Rick Wise, a Leerink Swann & Co. analyst in New York, in a note to clients. Still, the research is likely to cost Medtronic sales, said Jan David Wald, a Stanford Group Co. analyst in Boston, today in a telephone interview. ``To the extent that Medtronic has been making such a strong claim on safety, you know it can't help them, and it can't make investors and doctors feel more confidence about using their stent,'' Wald said. Patients getting Endeavor had more heart attacks and deadly stent thrombosis blood clots than those getting Johnson & Johnson's older drug-coated Cypher stent, the registry of more than 2,000 patients treated in Denmark found. They also were more likely to have arteries that re-clogged and required additional treatment, the study showed. Second Study A second study, known as Western Denmark, also found higher rates of re-clogging, known as restenosis, and greater need for new surgery in Endeavor patients. Patients getting Medtronic's device also had higher death rates, though the researchers warned against making too much of the finding. A third trial showed Endeavor wasn't better than Xience at preventing clots. The Western Denmark researchers through they would find Endeavor patients had a bit more restenosis, when the artery re- clogs, and significantly lower safety risks such as clotting than those getting Cypher, said Leif Thuesen, the lead investigator and director of the cardiac catheterization laboratory at Skejby Hospital in Aarhus. ``We were really surprised that the safety wasn't better than with Cypher,'' Thuesen said. ``We had expected the opposite. It's fair to have a bit higher restenosis rate in case the safety is better. This seems not to be the case here.'' Thuesen stopped using the Endeavor stent as a result of the trial. He now prefers a newer Medtronic device called Endeavor Resolute that is available in Europe. Drug Treatments Patients in the study have only been followed for about nine months and most are taking drugs including aspirin and Plavix from Bristol-Myers Squibb Co. and Sanofi-Aventis SA to prevent clots, said Lassen, lead investigator in the Sort-Out III study. Once they stop the medicine, more Cypher patients may develop problems, he said. In addition, the sickest patients may have been given Endeavor, skewing the findings, he said. ``We have to be careful, but I think there are some signals in what we have seen today,'' Lassen said during a press conference. ``It's only half the story,'' he said, with more information to come as the study continues. ``But the signal in the registry is still there. I think it's kind of a warning of a safety problem.'' Endeavor's portion of U.S. stent sales fell to 13 percent in the third quarter, down from 18 percent the prior three months, said Michael Weinstein, a J.P. Morgan Chase & Co. analyst, in an Oct. 8 note to clients. Xience and a copy sold by Boston Scientific called Promus are now the top-selling stents in the country, Abbott said this week. `Far From Proof' ``These data are interesting, but they are far from extraordinary proof,'' said Daniel Beach, a spokesman for Minneapolis-based Medtronic, in an e-mail. He said the findings were unusually positive in the Cypher-treated patients. Medtronic is conducting a three-year study known as Protect with 8,800 patients to definitively determine if Endeavor reduces the risk of blood clots more than a year after the device is implanted. The results will be available in 2011. The third study presented today, Estrofa, found Endeavor did no better than Xience at preventing blood clots when used at Spanish hospitals. The rate of clotting among the 3,300 patients with Endeavor was 1.5 percent, compared with 1.4 percent for Xience, said lead investigator Jose de la Torre Hernandez at a news conference. The results came one year after the stent was implanted and Hernandez cautioned longer-term data might change the picture. Endeavor's advantage over other stents has shown up at two years and beyond in other studies. >> Never trust all these marketing Bull Shit. Medtronic has been touting their Endeavor stent as the best in terms of Late Stent Thrombosis. Well, independent studies do not lie. Now I wonder what is their next line of sales pitch..! |
|||||
| Useful To Me Not Useful To Me | ||||||
|
ironside
Member |
17-Oct-2008 07:05
|
|||||
|
x 1
x 0 Alert Admin |
Bengster has given a lot of information on BIG at in forum, I appreciated his effort, thank you Bengster. However, he also gave a lot of his own gut feeling which were not based on fact, example sometime ago, when the price was about 80cents, he kept urging everyone to buy, saying it is a 'lalong now, it will not be at this price.....' I wonder whether Bengster has any ulterior motive in talking as if he was very sure, when in fact it was only his feeling. His very passionate postings here definitely influence many of us reading this forum to buy at 80 cents and hold when there was profit to be made. At this price of 25 cents, many of us lost a lot. I do not blame anyone, I just have to be more careful. Anyway, I have just got another 5 lots at 23 cents yesterday.....cheers :-) |
|||||
| Useful To Me Not Useful To Me | ||||||
|
snowella
Member |
16-Oct-2008 23:15
|
|||||
|
x 0
x 0 Alert Admin |
Hi XMG888....I wasn't exactly 'cheers first' even i feel it is a further piece of positive news. Cheers = an informal way of saying 'goodbye' And yes, I agree that good products must be able to sell too.
|
|||||
| Useful To Me Not Useful To Me | ||||||
|
|
||||||
|
XiaoMaGe888
Senior |
16-Oct-2008 14:58
|
|||||
|
x 0
x 0 Alert Admin |
Dun Cheers first,after good news release price down.but I think at this price is best time to buy. (personal view) Hope will
|
|||||
| Useful To Me Not Useful To Me | ||||||
|
dcang84
Veteran |
16-Oct-2008 07:58
|
|||||
|
x 0
x 0 Alert Admin |
Spot on.
|
|||||
| Useful To Me Not Useful To Me | ||||||
|
novena_33
Veteran |
16-Oct-2008 05:53
|
|||||
|
x 0
x 0 Alert Admin |
well..they still need to prove by selling their product.... and not keep saying how good it is...
|
|||||
| Useful To Me Not Useful To Me | ||||||
|
JustForFun
Member |
15-Oct-2008 19:22
|
|||||
|
x 0
x 0 Alert Admin |
Biosensors’ Drug‐Eluting Stent Demonstrates Superior Strut Coverage to Industry Leading Drug‐Eluting Stent
Washington, DC, 14 October 2008 – In the first study of its kind, a new medical imaging technique showed that lesions treated with a Biosensors’ biolimus drug‐eluting stent were more than 10 times more likely to have nearly‐complete stent‐strut coverage at nine months than those treated with the industry standard drug‐eluting stent. Uncovered stent struts may disrupt blood flow within the vessel and could be a contributing factor towards stent thrombosis. The results of the Optical Coherence Tomography (“OCT”) sub‐set analysis, comparing post‐implantation tissue coverage between two drugeluting stents in a large‐scale, randomized trial, were presented yesterday at the 2008 Transcatheter Cardiovascular Therapeutics (“TCT”) conference in Washington, DC. The pre‐defined sub‐group analysis showed lesions treated with the Biosensors’ biolimus‐eluting stent, which uses an abluminally coated biodegradable polymer, had significantly higher rates of complete tissue coverage and lower rates of poorly apposed stent struts than the industry standard drug‐eluting stent, Johnson & Johnson Cordis’ CYPHER SELECT™ (“Cypher”). In addition to the newly released OCT sub‐group data, Biosensors also released 12‐month follow‐up data from its landmark LEADERS trial (Limus Eluted from A Durable versus ERodable Stent coating), the first head‐to‐head randomized study between the two drug‐eluting stent systems in a ‘real world, all comers’ population using clinical results as its primary endpoint. At 12‐months, the Biosensors stent continues to show equivalent safety and efficacy as compared to the Cypher stent. The OCT analysis, a subset of the LEADERS study, included 46 patients who underwent OCT imaging at 9‐months. In total, the study examined 11,068 struts in 64 lesions. At nine months, 39.4 percent of lesions treated with Cypher had more than five percent uncovered struts, as compared with only 3.6 percent of lesions that received the Biosensors stent (p=0.005). In addition, lesions treated with Cypher were more than 10 times more likely to have more than five percent malapposition (9.7 percent vs. 0.9 percent, p=0.06). Commenting on the study, lead investigator Prof. Carlo Di Mario, of London’s Royal Brompton Hospital, said, “We observed a thin layer of intimal coverage, with an average thickness of approximately 50 microns, on most struts in both stents, explaining the similar efficacy in preventing restenosis, an observation supported by the 12 month results from the main study. The Biosensors stent, however, showed a significantly better level of nearly complete strut coverage, possibly due to the biodegradable polymer. The better intimal coverage achieved by the Biosensors stent at 9 months possibly anticipates a lower risk of late stent thrombosis. This needs to be confirmed by the planned long‐term follow‐up, lasting for as long as five years after stent implantation.” Of the 1,707 patients enrolled in the LEADERS trial, 1,666, or 97.6 percent, were included in the 12‐month follow‐up. The primary endpoint of the non‐inferiority trial was cardiac death, myocardial infarction or clinically‐indicated target vessel revascularization (“TVR”) at 9‐months. The 9‐month results for the composite endpoint, released in September 2008, were 9.2 percent for patients who received the Biosensors stent and 10.5 percent for patients who received the Cypher stent (p=0.003). At 12 months, the rate for the Biosensors group was 10.7 percent and 12.2 percent for the Cypher group. In terms of efficacy, the likelihood of any repeat vascularisation was 7.8 percent for patients who received the Biosensors stent and 10.1 percent for those who received Cypher. "I am very happy with the 12‐month results of the LEADERS study, which confirm the 9‐month results”, commented Professor Patrick Serruys, head of the interventional department at Erasmus University’s Thoraxcenter in Rotterdam, The Netherlands. “The Biosensors’ drug‐eluting stent, combining the novel biolimus drug and an abluminal biodegradable polymer, is a very promising technology for our patients’ long term benefit", Serruys added. Professor Stephan Windecker, head of the department of cardiovascular diseases at the University Hospital Bern, Switzerland, and principal investigator for the LEADERS trial commented, “Since the product became commercially available earlier this year, we have had significant experience using Biosensors’ drug‐eluting stent system, with excellent clinical outcomes and device success rates, confirming the positive results achieved with the LEADERS study. I believe that these stents represent true next generation drug‐eluting stent technology". |
|||||
| Useful To Me Not Useful To Me | ||||||
|
snowella
Member |
15-Oct-2008 18:08
|
|||||
|
x 0
x 0 Alert Admin |
Hi all, i just read a press article re Biosensors superior stent results over J&J's in SGX announcement by BIG...It is a positive confirmation ..... should be a cheerful piece of news.... Sorry i dont know how to post it here.... so please go to SGX website.... Cheers..... ps i am new here and am invested in a small way. | |||||
| Useful To Me Not Useful To Me | ||||||
|
wb1931
Member |
15-Oct-2008 17:43
|
|||||
|
x 0
x 0 Alert Admin |
Hi everyone, I have been following this forum for about a year now and my conclusion is that this company's sales (< 100 mil) in a multi billion dollar industry is too small to be a major player. | |||||
| Useful To Me Not Useful To Me | ||||||
|
ekekeg
Veteran |
15-Oct-2008 10:04
|
|||||
|
x 0
x 0 Alert Admin |
abc2xyz, I also agree with xiaoMage that you should not surrender. Just read what I got this morning: Strategy: Flight to safety Summary: Frozen credit markets around the world have called for drastic moves by central banks to restore confidence and to induce banks to resume their lending activity. In light of this, companies that are highly geared and those that face near term refinancing obligations have come under intense scrutiny for two key reasons: concerns over the ability to secure refinancing and the fear of soaring finance costs. The deteriorating economic outlook poses additional challenges on firms to fulfill outstanding loan repayment obligations. Companies in strong cash positions are deemed to be in a stronger position than those with high gearing, especially if debt obligations require near-term refinancing. Under our coverage, some of the defensive companies that we continue to favour, and have net cash positions, include Biosensors Int’l (BUY, S$1.02), Ezra (BUY, S$3.30), SembCorp Marine (BUY, S$4.98) and Singapore Press Holdings (BUY, S$5.14). (Research Team from OCBC) Cheers |
|||||
| Useful To Me Not Useful To Me | ||||||
|
abc2xyz
Senior |
15-Oct-2008 08:58
Yells: "A stock sucker always enriches the market makers" |
|||||
|
x 0
x 0 Alert Admin |
Thanks XiaoMaGe, Actually this counter can say say too low already for its perspective future (Not PE ration, but business prospects). I think about it.
|
|||||
| Useful To Me Not Useful To Me | ||||||
